ライフサイエンスコーパス: insulinotropic

1 Understanding loss of GIP's insulinotropic action in PI-CF may lead to novel insight

2 The insulinotropic action of glucagon, which is proportional

3 e, whereas 10 microM forskolin amplified the insulinotropic action of MP.

4 The insulinotropic actions of glucagon-like peptide 1 recept

5 Thus, the insulinotropic actions of pancreatic CRFR1 oppose the ac

6 st, is an exocrine hormone, which has potent insulinotropic actions similar to GLP-1 such as stimulat

7 is characterized by their glucose-dependent insulinotropic actions without risk of hypoglycemia.

8 ulate ketogenesis is severely limited by its insulinotropic actions.

9 MIN6 cell line almost completely eliminates insulinotropic activity of M3R.

10 slets, respectively, uniquely attenuated the insulinotropic activity of TAK-875, thus providing funct

11 atocyte growth factor (HGF) is a mitogen and insulinotropic agent for the beta-cell.

12 eptide-1 (GLP-1) receptor agonist and potent insulinotropic agent for type 2 diabetes patients; howev

13 e physiological importance as a postprandial insulinotropic agent is unknown.

14 oup recently reported the discovery of a new insulinotropic agent, cardiotoxin-I (CTX-I), from the Na

15 ions within the basal range or to additional insulinotropic agents besides GLP mediating the antidiab

16 Extended insulinotropic and antihyperglycemic actions were also e

17 able interest in GIPR agonism to enhance the insulinotropic and extrapancreatic effects of GIP, there

18 We demonstrate insulinotropic and glucose-lowering effects of endogenou

19 Fgf3-elicited insulinotropic and glucose-lowering responses were recap

20 glucagon-like peptide-1 (7-36) amide is both insulinotropic and insulinomimetic and has been suggeste

21 is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimu

22 ate cholecystokinin-8 in the presence of the insulinotropic antidiabetes compounds tolbutamide, glibe

23 The insulinotropic characterization of myricetin was perform

24 Sulfonylurea derivatives exert their insulinotropic effect by binding to the SUR1 subunit of

25 G elicited a protracted glucose-lowering and insulinotropic effect in high fat-fed mice.

26 asma levels, still had an early, short-lived insulinotropic effect in type 2 diabetes.

27 Glp1r-/- mice results from the loss of a non-insulinotropic effect mediated by the Glp1r.

28 -1) in the hyperglycemic state abolished the insulinotropic effect of a physiological dose of GLP-1 a

29 An insulinotropic effect of dairy was not observed.

30 receptor antagonist, we determined that the insulinotropic effect of dibenzazepine was mediated thro

31 The highest insulinotropic effect of exendin-4 was also observed in

32 vention of PKA activation indicated that the insulinotropic effect of genistein is primarily mediated

33 anism is not important for regulation of the insulinotropic effect of GIP in subjects with T2DM.

34 er OATP1B3 functions as a determinant of the insulinotropic effect of glibenclamide on the tissue lev

35 insulin secretion-significantly enhances the insulinotropic effect of glibenclamide without affecting

36 In mice, the insulinotropic effect of glucagon is glucose dependent a

37 They also show, however, that the insulinotropic effect of individual fatty acids spans a

38 Insulin sensitivity improved, but the insulinotropic effect of infused GIP was unchanged follo

39 ulin secretion and, instead, antagonizes the insulinotropic effect of Oxo-M and CCh-induced Ca(2+) up

40 e in amidated GLP-1, which can then exert an insulinotropic effect on the remaining beta cells.

41 iabetes by virtue of 1) their powerful acute insulinotropic effect, 2) their ability to exacerbate in

42 ssion by small interfering RNA blocked 43RFa insulinotropic effect, but not the insulinostatic action

43 f the cAMP/PKA signaling cascade to exert an insulinotropic effect, thereby providing a novel role of

44 combination with 10 microM forskolin had no insulinotropic effect.

45 reduced this excursion, due to a synergistic insulinotropic effect.

46 GLP-1 exerts important insulinotropic effects after RYGB and ILM, but the enhan

47 These studies characterize the insulinotropic effects of an early-stage, small molecule

48 On the one hand, statins abolish the insulinotropic effects of bile acids and on the other ha

49 arriers, we observed: 1) hypoinsulinemia, 2) insulinotropic effects of both GIP and GLP-1, 3) additiv

50 T) and hyperglycemic clamp characterized the insulinotropic effects of compounds in vivo.

51 is an important mechanism for mediating the insulinotropic effects of GLP-1.

52 chanistic insight into the recently reported insulinotropic effects of NMDAR antagonists and therefor

53 s a naturally occurring incretin with potent insulinotropic effects the action of which is attenuated

54 n-sensitive subjects: the transcripts of the insulinotropic glucose-dependant peptide (GIP) and of th

55 Glucose-induced secretion of insulinotropic hormone (GIP) and glucagon-like peptide 1

56 the blood glucose-lowering properties of an insulinotropic hormone (glucagon-like peptide-1, also kn

57 peptide-1 (GLP-1) is an intestinally derived insulinotropic hormone currently under investigation for

58 The insulinotropic hormone GLP-1 (glucagon-like peptide-1) i

59 MP, and stimulates the release of the potent insulinotropic hormone GLP-1, resulting in a promising d

60 Here, we show that the insulinotropic hormone glucagon-like peptide (GLP)-1, wh

61 possible therapeutic agent for NIDDM is the insulinotropic hormone glucagon-like peptide 1 (GLP-1).

62 Glucagon-like peptide 1 (GLP-1), an insulinotropic hormone normally synthesised in the intes

63 Glucagon-like peptide 1 (GLP-1) is an insulinotropic hormone released after nutrient ingestion

64 etabolic inactivation of a glucose-dependent insulinotropic hormone, glucagon-like peptide 1 (GLP-1),

65 tivation of the GLP-1R, we characterized the insulinotropic mechanism of BETP.

66 the ERbeta selective agonist WAY200070 as an insulinotropic molecule.

67 To determine whether insulinotropic off-target effects of PEG-IGF-I caused th

68 d on the incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1

69 like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) concentrations were measure

70 like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) has been found to be dimini

71 Glucose-dependent insulinotropic peptide (GIP) induces production of inter

72 Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid peptide

73 like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) is sparsely described.

74 like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors, can be overexpre

75 Like Peptide-2 (GLP-2) and Glucose-dependent Insulinotropic Peptide (GIP) was measured pre- and posto

76 like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), can increase the cAMP cont

77 treatments (glucose, KCl, glucose-responsive insulinotropic peptide (GIP), forskolin) that act upon g

78 of cholecystokinin (CCK), glucose-dependent insulinotropic peptide (GIP), glucagon, and neurotensin

79 ll intestine to study the secretion of gluco-insulinotropic peptide (GIP), glucagon-like peptide-1 (G

80 were assayed for insulin, glucose-dependent insulinotropic peptide (GIP), glucose and acetaminophen.

81 like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).

82 lucagon-like peptide 1 and glucose-dependent insulinotropic peptide (the incretin hormones), which in

83 lucagon-like peptide 1 and glucose-dependent insulinotropic peptide and in the regulation of plasma c

84 , body mass index, fasting glucose-dependent insulinotropic peptide and type 2 diabetes, with B-arres

85 tylmethylxanthine, and the glucose-dependent insulinotropic peptide inhibited AMPK activity and reduc

86 eptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic peptide receptor (GIPR) agonistic analogs

87 glucagon-like peptide 1 or glucose-dependent insulinotropic peptide receptor agonists largely correct

88 agon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestina

89 , C-peptide, glucagon, and glucose-dependent insulinotropic peptide were approximately 10-23% lower (

90 ast, postprandial insulin, glucose-dependent insulinotropic peptide, and pancreatic polypeptide respo

91 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide, and peptide YY (PYY) were measur

92 Fasting total GLP-1, glucose-dependent insulinotropic peptide, and PYY levels were similar betw

93 lucagon-like peptide-1 and glucose-dependent insulinotropic peptide, as well as ghrelin and peptide Y

94 ditional hormones, such as glucose-dependent insulinotropic peptide, glucagon and amylin, to achieve

95 a decrease in metabolic endotoxemia, glucose insulinotropic peptide, glucose intolerance, lipogenesis

96 , glucagon-like peptide 1, glucose-dependent insulinotropic peptide, insulin, glucagon, total amino a

97 lucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are two important incretin

98 antagonists, and combined glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor

99 y enhanced the insulin and glucose-dependent insulinotropic polypeptide (but not glucagon-like peptid

100 Glucose-dependent insulinotropic polypeptide (GIP) (also known as gastric

101 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) account for up to 60% o

102 like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) act directly in the bra

103 Resistance to glucose-dependent insulinotropic polypeptide (GIP) action may occur throug

104 Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are incretins

105 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.

106 t occurred despite similar glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

107 The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

108 Plasma glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

109 atment with tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

110 retin effect," mediated by glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

111 influence the magnitude of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

112 Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like pepti

113 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are altered in the dise

114 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones t

115 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two incretins secre

116 The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) augments glucose-depend

117 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) can enhance pancreatic

118 Glucose-dependent insulinotropic polypeptide (GIP) communicates nutrient i

119 anscript and a decrease in glucose-dependent insulinotropic polypeptide (GIP) gene transcripts were o

120 Glucose-dependent insulinotropic polypeptide (GIP) has been suggested to h

121 milar changes in GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) in response to oral glu

122 hy men, the involvement of glucose-dependent insulinotropic polypeptide (GIP) in splanchnic blood flo

123 and infusion of exogenous glucose-dependent insulinotropic polypeptide (GIP) in the splanchnic regio

124 tration of the gut hormone glucose-dependent insulinotropic polypeptide (GIP) increases splanchnic bl

125 Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid gast

126 Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid pept

127 Glucose-dependent insulinotropic polypeptide (GIP) is a member of a struct

128 Glucose-dependent insulinotropic polypeptide (GIP) is a physiological insu

129 Since glucose-dependent insulinotropic polypeptide (GIP) is a strong stimulator

130 Glucose-dependent insulinotropic polypeptide (GIP) is an endogenous hormon

131 Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone

132 The glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone

133 Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone

134 Glucose-dependent insulinotropic polypeptide (GIP) is glucagonotropic, and

135 Exploitation of glucose-dependent insulinotropic polypeptide (GIP) is hindered by its shor

136 Glucose-dependent insulinotropic polypeptide (GIP) is released from the up

137 sensing to increase plasma glucose-dependent insulinotropic polypeptide (GIP) levels and reduce feedi

138 of the enteroinsular axis, glucose-dependent insulinotropic polypeptide (GIP) may play a critical rol

139 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) play critical roles in

140 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) play important physiolo

141 Glucose-dependent insulinotropic polypeptide (GIP) potentiates glucose-sti

142 Glucose-dependent insulinotropic polypeptide (GIP) promotes glucose-depend

143 ought to determine whether glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) agonism

144 tagonism or agonism of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) prevent

145 or agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists in ma

146 Targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor may enhance th

147 1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor transduce nutr

148 of its target genes (Pdx1, glucose-dependent insulinotropic polypeptide (GIP) receptor, and pyruvate

149 f the incretin family, the glucose-dependent insulinotropic polypeptide (GIP) receptor.

150 neurons express GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, and vagal ne

151 ipid infusion to stimulate glucose-dependent insulinotropic polypeptide (GIP) secretion and decrease

152 GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) secretions are unaltere

153 se, insulin, glucagon, and glucose-dependent insulinotropic polypeptide (GIP) were analyzed.

154 Insulin and glucose-dependent insulinotropic polypeptide (GIP) were higher for 25WG ve

155 ike peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured after the

156 ike peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured.

157 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) are secreted from ente

158 loyed to produce PEGylated glucose-dependent insulinotropic polypeptide (GIP), a protein with potenti

159 Glucose-dependent insulinotropic polypeptide (GIP), an incretin hormone se

160 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and cholecystokinin (l

161 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon bind to r

162 ist activity for glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like pept

163 ed plasma levels of GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and insulin, and impro

164 cretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), by inhibiting their br

165 on-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK),

166 A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3-30)NH2, was rece

167 th agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon re

168 [gastrin, cholecystokinin, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide

169 highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-

170 One of these incretins, glucose-dependent insulinotropic polypeptide (GIP), has garnered much atte

171 -like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP), have advanced the trea

172 er major incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), is relatively unexplor

173 like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), play an important role

174 like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), slow gastric emptying,

175 -like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP), the 2 major incretins

176 Glucose-dependent insulinotropic polypeptide (GIP), unlike glucagon-like p

177 ll intestine that produces glucose-dependent insulinotropic polypeptide (GIP), xenin, and potentially

178 n-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

179 lucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide (GIP).

180 like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

181 rs for glucagon and/or the glucose-dependent insulinotropic polypeptide (GIP).

182 nd can be activated by the glucose-dependent insulinotropic polypeptide (GIP).

183 n medications include dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs, dipeptidyl pe

184 e, amino acids, plus 10 nM glucose-dependent insulinotropic polypeptide (GIP); and (4) 2 mM glucose.

185 (GCG) receptor (GCGR), and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric i

186 r with the closely related glucose-dependent insulinotropic polypeptide (GIPR) and glucagon (GCGR) re

187 and decreased ghrelin and glucose-dependent insulinotropic polypeptide (P < 0.05).

188 Glucose-dependent insulinotropic polypeptide [also known as gastric inhibi

189 like peptide 1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]), whereas metformin may

190 tolerability of novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist ti

191 irzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist un

192 efficacy of tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, c

193 Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (

194 effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 r

195 ty of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 r

196 Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 r

197 Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 r

198 irzepatide, a once-weekly, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 r

199 d safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 r

200 , a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 r

201 ponses of intact GLP-1 and glucose-dependent insulinotropic polypeptide and lowered glucose responses

202 gonists and possibly GLP-1/glucose-dependent insulinotropic polypeptide co-agonists (e.g., tirzepatid

203 e, insulin, C-peptide, and glucose-dependent insulinotropic polypeptide concentrations were significa

204 lucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide have been postulated to play

205 nction (P < 0.01), and reductions in glucose-insulinotropic polypeptide levels (P < 0.001), glucagon

206 e same PPRE within the rat glucose-dependent insulinotropic polypeptide receptor (GIP-R) promoter seq

207 essing a dominant-negative glucose-dependent insulinotropic polypeptide receptor (GIPR(dn)) reveal pr

208 nt studies have found that glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism can e

209 e therapeutic potential of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism.

210 e is a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the gluca

211 de-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) has emerged a

212 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) in mice have

213 Targeting of the glucose-dependent insulinotropic polypeptide receptor (GIPR) is an emergin

214 musk shrews), we show that glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling blo

215 agonists targeting GLP-1R, glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon

216 To study active GLP-1, glucose-dependent insulinotropic polypeptide receptor (Gipr)-deficient mic

217 onism or antagonism of the glucose-dependent insulinotropic polypeptide receptor (GIPR).

218 domized to the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like pe

219 howed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like pe

220 ide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism and that

221 lucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effe

222 001), and no difference in glucose-dependent insulinotropic polypeptide responses compared with sham-

223 lucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide secretion were lower after lu

224 ction of glucagon-like peptide-1 and glucose-insulinotropic polypeptide were assessed during a meal t

225 peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for m

226 cholecystokinin), K-cells (glucose-dependent insulinotropic polypeptide) and L-cells, short-chain fat

227 n-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), are gut hormones secreted i

228 peptide-1 (GLP-1) and GIP (glucose-dependent insulinotropic polypeptide), in heart failure pathophysi

229 peptide-1 (GLP-1) and GIP (glucose-dependent insulinotropic polypeptide), respectively.

230 effects of emerging GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonis

231 ral gut hormones (insulin, glucose-dependent insulinotropic polypeptide, and glucagon-like peptide 1)

232 ovel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and

233 7943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and

234 like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, increases in proportion to m

235 (GLP-1), ghrelin, leptin, glucose-dependent insulinotropic polypeptide, insulin, and glucose were co

236 y and beta-cell function and reduced glucose-insulinotropic polypeptide, leptin, and glucagon product

237 apart from GLP-1, such as glucose-dependent insulinotropic polypeptide, stromal-derived factor-1alph

238 els of the other incretin, glucose-dependent insulinotropic polypeptide, were not as profoundly affec

239 lucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.

240 ns of endogenous GLP-1 and glucose-dependent insulinotropic polypeptide.

241 d postprandial response of glucose-dependent insulinotropic polypeptide.

242 stokinin, somatostatin, or glucose-dependent insulinotropic polypeptide.

243 ucagon-like peptide-1; and glucose-dependent insulinotropic polypeptide.

244 tide only), tirzepatide (a glucose-dependent insulinotropic polypeptide/GLP-1 agonist), phentermine-t

245 t loss, GLP-1 agonists and glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists can a

246 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 recep

247 Glucose-dependent-insulinotropic-polypeptide concentrations increased duri

248 Again, lard oil exhibited greater insulinotropic potency.

249 lts provide one explanation for differential insulinotropic potential of incretins in human T2D and p

250 ated to its anti-oxidant, anti-apoptotic and insulinotropic properties.

251 tion of PI3Kgamma blunted the exocytotic and insulinotropic response to GIP receptor activation, wher

252 Insulinotropic responses in clonal beta-cells were simil

253 number and area, as well beta-cell area and insulinotropic responsiveness, were dramatically improve

254 ionally linked to a beta-arrestin 2-mediated insulinotropic signaling axis.

255 eceptor mobilization of cAMP is the critical insulinotropic signaling event.